MedTrace Logo

Tumor Characteristics and Survival Rate of HER2-Low Breast Cancer Patients

NCT05754047 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3582

Last updated 2023-03-03

No results posted yet for this study

Summary

In this large-scale cross-sectional study, we evaluated disease-free survival (DFS), overall survival (OS), and clinicopathological characteristics of BC patients from 1991 to 2022, retrospectively. We recruited patients referred to the Cancer Research Center in Tehran, Iran, and their HER2 status, which is classified as HER2-low, HER2-positive, or HER2-negative, was obtained from prospectively maintained registries. we aimed to dive more deeply into the clinicopathological characteristics and survival features of HER2-low breast cancer patients and campared it with HER2-negative and HER2-positive groups.

Question 1: Is HER2-low breast cancer (BC) a new subtype in the standard classification of BCs? Question 2: How is the DFS and OS rate of HER2-low breast cancer patients in comparison with HER2-negative and HER2-positive groups?

Conditions

  • HER2 Low Breast Carcinoma

Interventions

DIAGNOSTIC_TEST

immunohistochemistry (IHC) and in situ hybridization (ISH) Test

These tests are usually applied for breast cancer patients to assist the surgeon to better understand the clinicopathological characteristics and survival features of tumors

Sponsors & Collaborators

  • Mahdis Bayat

    lead OTHER

Principal Investigators

  • Mohammad Esmail Akbari, Professor · Cancer Research Center, Shohadaye Tajrish Hospital, Shahid Beheshti University of Medical Sciences

Eligibility

Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
1991-04-30
Primary Completion
2022-03-31
Completion
2022-03-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05754047 on ClinicalTrials.gov